Last reviewed · How we verify
Aflibercept (Regeneron, USA)
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting angiogenesis and vascular permeability.
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting angiogenesis and vascular permeability. Used for Metastatic colorectal cancer (in combination with chemotherapy), Wet age-related macular degeneration, Diabetic macular edema.
At a glance
| Generic name | Aflibercept (Regeneron, USA) |
|---|---|
| Also known as | Eylea® |
| Sponsor | Cinnagen |
| Drug class | VEGF inhibitor (soluble decoy receptor) |
| Target | VEGF-A, VEGF-B, PlGF (Placental Growth Factor) |
| Modality | Biologic |
| Therapeutic area | Oncology, Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their native receptors on endothelial cells, thereby suppressing new blood vessel formation and reducing pathological vascular leakage. This mechanism is particularly effective in conditions driven by excessive angiogenesis.
Approved indications
- Metastatic colorectal cancer (in combination with chemotherapy)
- Wet age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion
Common side effects
- Hypertension
- Proteinuria
- Hemorrhage
- Thromboembolic events
- Gastrointestinal perforation
- Fatigue
- Diarrhea
Key clinical trials
- Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aflibercept (Regeneron, USA) CI brief — competitive landscape report
- Aflibercept (Regeneron, USA) updates RSS · CI watch RSS
- Cinnagen portfolio CI